Latest & greatest articles for alzheimer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Alzheimer’s disease

Alzheimer’s disease is a chronic neurodegenerative disease responsible for the majority of cases of dementia. This progressive disease disrupts memory and thinking due to an accumulation of plaques and tangles in the brain. As the disease progresses, these get progressively worse.

What causes Alzheimer’s diseases is poorly understood, although there is a strong genetic component which could account for the majority (~70%) of the risk. Other risk factors have been identified, such as depression, head injuries and hypertension. Alzheimer’s disease is typically a disease of older people.

Although Alzheimer’s disease cannot currently be cured but it can be managed. With cholinesterase inhibitors being a common intervention as well as memantine (an NMDA receptor antagonist) and psychosocial interventions.

Trip has an extensive collection of research evidence and articles relating to Alzheimer’s disease including clinical guidelines, systematic reviews, synopses, clinical trials and case reports.

Top results for alzheimer

101. A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease. 23883379 2013 07 25 2013 08 02 2016 10 25 1533-4406 369 4 2013 Jul 25 The New England journal of medicine N. Engl. J. Med. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. 341-50 10.1056/NEJMoa1210951 Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein (...) . Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog

NEJM2013

103. [Specialized services for people with alzheimer's disease]

[Specialized services for people with alzheimer's disease] [Specialized services for people with alzheimer's disease] [Specialized services for people with alzheimer's disease] L'Institut national d'excellence en sante et en services sociaux (INESSS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation L'Institut national d'excellence en sante (...) et en services sociaux (INESSS). [Specialized services for people with alzheimer's disease] Montreal: L'Institut national d'excellence en sante et en services sociaux (INESSS). Volume 8(16). 2012 Authors' objectives The assessment questions covered the necessary criteria and parameters for the service offerings: the target clientele or critical masses, the nature and modalities of service delivery, human or professional resources, and the clinical processes for: memory clinics; Alzheimer support

Health Technology Assessment (HTA) Database.2012

104. Variant TREM2 as Risk Factor for Alzheimer's Disease.

Variant TREM2 as Risk Factor for Alzheimer's Disease. PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Select item 23151315 1. 2013 Jan 10;368(2):182-4. doi: 10.1056/NEJMe1213157. Epub 2012 Nov 14. Variant TREM2 as risk factor for Alzheimer's disease. , . Comment in [N Engl J Med. 2013] Comment on [N Engl J Med. 2013] [N Engl J Med. 2013] PMID: 23151315 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances

NEJM2012

105. Variant of TREM2 Associated with the Risk of Alzheimer's Disease.

Variant of TREM2 Associated with the Risk of Alzheimer's Disease. BACKGROUND: Sequence variants, including the ε4 allele of apolipoprotein E, have been associated with the risk of the common late-onset form of Alzheimer's disease. Few rare variants affecting the risk of late-onset Alzheimer's disease have been found. METHODS: We obtained the genome sequences of 2261 Icelanders and identified sequence variants that were likely to affect protein function. We imputed these variants (...) into the genomes of patients with Alzheimer's disease and control participants and then tested for an association with Alzheimer's disease. We performed replication tests using case-control series from the United States, Norway, The Netherlands, and Germany. We also tested for a genetic association with cognitive function in a population of unaffected elderly persons. RESULTS: A rare missense mutation (rs75932628-T) in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2), which

NEJM2012 Full Text: Link to full Text with Trip Pro

106. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment

Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment Zhang S, Han D, Tan X, Feng J, Guo (...) Y, Ding Y CRD summary This article concluded that 18 F-fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) and 11 C-Pittsburgh Compound B-positron emission tomography (PIB-PET) were accurate non-invasive tests for prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment. Methodological limitations and generally moderate-to-low pooled estimates of sensitivity and specificity mean these conclusions seem optimistic. Authors' objectives To assess

DARE.2012

107. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer`s disease (GuidAge): a randomised placebo-controlled trial

Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer`s disease (GuidAge): a randomised placebo-controlled trial 22959217 2012 09 21 2012 11 29 2016 11 25 1474-4465 11 10 2012 Oct The Lancet. Neurology Lancet Neurol Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. 851-9 10.1016/S1474-4422(12)70206-5 S1474-4422(12)70206-5 Prevention strategies are urgently needed to tackle (...) the growing burden of Alzheimer's disease. We aimed to assess efficacy of long-term use of standardised ginkgo biloba extract for the reduction of incidence of Alzheimer's disease in elderly adults with memory complaints. In the randomised, parallel-group, double-blind, placebo-controlled GuidAge clinical trial, we enrolled adults aged 70 years or older who spontaneously reported memory complaints to their primary-care physician in France. We randomly allocated participants in a 1:1 ratio according

EvidenceUpdates2012

108. [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine]

[Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin [Cholinesterase inhibitors in Alzheimer's disease - supplementary (...) commission: rivastigmine patches and galantamine] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin. [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cologne: Institut fuer

Health Technology Assessment (HTA) Database.2012

109. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease.

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. BACKGROUND: The order and magnitude of pathologic processes in Alzheimer's disease are not well understood, partly because the disease develops over many years. Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to determine the sequence and magnitude of pathologic changes that culminate in symptomatic disease. METHODS: In this prospective, longitudinal study, we analyzed (...) data from 128 participants who underwent baseline clinical and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests. We used the participant's age at baseline assessment and the parent's age at the onset of symptoms of Alzheimer's disease to calculate the estimated years from expected symptom onset (age of the participant minus parent's age at symptom onset). We conducted cross-sectional analyses of baseline data in relation to estimated years from expected symptom

NEJM2012 Full Text: Link to full Text with Trip Pro

110. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease.

Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography (...) Citation manager Format Create File 1 selected item: 22711111 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Jun 19;156(12):JC6-10. doi: 10.7326/0003-4819-156-12-201206190-02010. ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. 1 . 1 St. Vincent's Health Network

Annals of Internal Medicine2012

111. Adverse outcomes after hospitalization and delirium in persons with Alzheimer disease.

Adverse outcomes after hospitalization and delirium in persons with Alzheimer disease. BACKGROUND: Hospitalization, frequently complicated by delirium, can be a life-changing event for patients with Alzheimer disease (AD). OBJECTIVE: To determine risks for institutionalization, cognitive decline, or death associated with hospitalization and delirium in patients with AD. DESIGN: Prospective cohort enrolled between 1991 and 2006 into the Massachusetts Alzheimer's Disease Research Center (MADRC

Annals of Internal Medicine2012 Full Text: Link to full Text with Trip Pro

112. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom

An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom Getsios D, Blume S, Ishak KJ, MacLaine G, Hernandez L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective of the study was to evaluate the cost-effectiveness of early assessment and treatment for Alzheimer’s disease compared with treatment after diagnosis or no treatment. The authors concluded that there were substantial benefits to a programme of early assessment and treatment. The quality of the study methods was satisfactory. The results were well

NHS Economic Evaluation Database.2012

114. Dementia From Alzheimer Disease and Mixed Pathologies in the Oldest Old

Dementia From Alzheimer Disease and Mixed Pathologies in the Oldest Old 22550192 2012 05 02 2012 05 04 2016 10 19 1538-3598 307 17 2012 May 02 JAMA JAMA Dementia from Alzheimer disease and mixed pathologies in the oldest old. 1798-800 10.1001/jama.2012.3556 James Bryan D BD Rush University Medical Center, Chicago, Illinois, USA. bryan_james@rush.edu Bennett David A DA Boyle Patricia A PA Leurgans Sue S Schneider Julie A JA eng R01AG33678 AG NIA NIH HHS United States P01AG14449 AG NIA NIH HHS (...) . 2008 Sep;65(9):1211-7 18779425 Age Factors Aged Aged, 80 and over Alzheimer Disease complications epidemiology pathology Cerebral Infarction complications epidemiology pathology Cohort Studies Female Humans Lewy Body Disease complications epidemiology pathology Male Prevalence NIHMS378341 PMC3368581 2012 5 3 6 0 2012 5 3 6 0 2012 5 5 6 0 ppublish 22550192 307/17/1798 10.1001/jama.2012.3556 PMC3368581 NIHMS378341

JAMA2012 Full Text: Link to full Text with Trip Pro

115. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer?s disease (review of TA111): a systematic review and economic model

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer?s disease (review of TA111): a systematic review and economic model The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and economic model Journals Library An error has occurred in processing the XML document An error occurred retrieving content

NIHR HTA programme2012

116. Age and diagnostic performance of Alzheimer disease CSF biomarkers

Age and diagnostic performance of Alzheimer disease CSF biomarkers 22302554 2012 02 14 2012 04 04 2016 11 25 1526-632X 78 7 2012 Feb 14 Neurology Neurology Age and diagnostic performance of Alzheimer disease CSF biomarkers. 468-76 10.1212/WNL.0b013e3182477eed Core CSF changes in Alzheimer disease (AD) are decreased amyloid β(1-42), increased total tau, and increased phospho-tau, probably indicating amyloid plaque accumulation, axonal degeneration, and tangle pathology, respectively (...) Research Support, Non-U.S. Gov't 2012 02 01 United States Neurology 0401060 0028-3878 0 Biomarkers 0 tau Proteins AIM IM Neurology. 2000 Jan 11;54(1):105-13 10636134 Acta Neuropathol. 2010 Apr;119(4):421-33 20204386 J Neural Transm Suppl. 2000;59:23-30 10961414 J Neurosci Res. 2001 Nov 1;66(3):510-6 11746370 Clin Chem. 2003 Jan;49(1):1-6 12507953 Lancet Neurol. 2002 Nov;1(7):426-36 12849365 J Intern Med. 2004 Sep;256(3):240-6 15324367 Dement Geriatr Cogn Disord. 2009;27(2):194-200 19225233 J Alzheimers

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

117. Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease

Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease 22323746 2012 02 21 2012 04 23 2016 11 25 1526-632X 78 8 2012 Feb 21 Neurology Neurology Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. 569-77 10.1212/WNL.0b013e318247caa1 DNA damage accumulation in brain is associated with the development of Alzheimer disease (AD), but newly identified protein markers of DNA damage have not been evaluated in the diagnosis of AD and other forms (...) 08 United States Neurology 0401060 0028-3878 0 Biomarkers 0 Peptide Elongation Factor 1 0 Stathmin EC 3.2.1.- Hexosaminidases EC 3.2.1.14 Chitinases AIM IM Nat Rev Neurol. 2012 Apr;8(4):178 22391481 Neurology. 2012 Feb 21;78(8):574 22323752 Adult Aged Aged, 80 and over Alzheimer Disease cerebrospinal fluid diagnosis enzymology Biomarkers cerebrospinal fluid Chitinases cerebrospinal fluid DNA Damage physiology Dementia cerebrospinal fluid diagnosis enzymology Diagnosis, Differential Female

EvidenceUpdates2012

118. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease

Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease Lachaine J, Beauchemin C, Legault M, Bineau S Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of adding memantine to the usual cholinesterase inhibitor treatment for patients with Alzheimer's disease. The authors concluded that the addition of memantine was cost-effective, compared with a cholinesterase inhibitor alone. The methods were

NHS Economic Evaluation Database.2012

119. Use it or Lose it- Do cognitive leisure activities protect against the development of Alzheimer?s?

Use it or Lose it- Do cognitive leisure activities protect against the development of Alzheimer?s? Use it or Lose it- Do cognitive leisure activities protect against the development of Alzheimer’s? | Clinical Correlations Use it or Lose it- Do cognitive leisure activities protect against the development of Alzheimer’s? March 30, 2012 By Courtney Cunningham, MD Faculty Peer Reviewed As the world population ages, enormous resources will be required to adequately care for persons suffering from (...) Alzheimer’s disease. The disease is the fifth leading cause of death for adults aged 65 years and older, and is estimated to affect 1 in 8 persons in this age group.[1,2] Despite recent advances, the cause of Alzheimer’s disease is not well understood. The FDA-approved medications in common use—donepezil (Aricept), galantamine (Razadyne), rivastigmine (Exelon), and memantine (Namenda)–help to manage symptoms; however there are no treatments available shown to stop or reverse the progression of the disease

Clinical Correlations2012

120. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study.

Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. OBJECTIVES: To relate cancer since entry into the Framingham Heart Study with the risk of incident Alzheimer's disease and to estimate the risk of incident cancer among participants with and without Alzheimer's disease. DESIGN: Community based prospective cohort study; nested age and sex matched case-control study. SETTING: Framingham Heart Study, USA. PARTICIPANTS: 1278 participants (...) with and without a history of cancer who were aged 65 or more and free of dementia at baseline (1986-90). MAIN OUTCOME MEASURES: Hazard ratios and 95% confidence intervals for the risks of Alzheimer's disease and cancer. RESULTS: Over a mean follow-up of 10 years, 221 cases of probable Alzheimer's disease were diagnosed. Cancer survivors had a lower risk of probable Alzheimer's disease (hazard ratio 0.67, 95% confidence interval 0.47 to 0.97), adjusted for age, sex, and smoking. The risk was lower among

BMJ2012 Full Text: Link to full Text with Trip Pro